FILING ANALYSIS · THURSDAY, NOVEMBER 12
Akari Therapeutics Plc AKTX — 8-K: Results of Operations and Financial Condition
neutral
The company announced the initiation of GLP toxicology studies for its lead candidate AKTX-101 and new preclinical findings demonstrating activity in models resistant to existing ADC therapies, but noted that the planned Phase 1 clinical trial in mid-2027 is subject to obtaining additional financing, implying a potential need for dilution.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →